Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 3/20 | 1.00 |
| ▸ | DRD3 | P35462 | 3/20 | 1.00 |
| ▸ | DRD1 | P21728 | 2/20 | 1.00 |
| ▸ | DRD4 | P21917 | 2/20 | 1.00 |
| ▸ | DRD5 | P21918 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | ADRA1D | P25100 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | ADRA1B | P35368 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.96 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.96 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.57 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.57 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29368857 | 1.00 | DRD2 (1.00) | DRD2DRD3DRD1DRD4DRD5 | |
| Hydrochloric Acid SCHEMBL4305739 | 0.98 | DRD2 (0.96) | DRD2DRD3DRD1DRD4DRD5 | |
| Bromide SCHEMBL1321255 | 0.98 | KDM4E (1.00) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL6674754 | 0.93 | DRD2 (0.87) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL10428293 | 0.92 | DRD2 (0.84) | DRD2DRD3DRD1DRD4DRD5 | |
| Dopamine SCHEMBL14919131 | 0.92 | DRD2 (0.84) | DRD2DRD3DRD1DRD4DRD5 | |
| Bromide SCHEMBL10744684 | 0.92 | KDM4E (0.88) | DRD2DRD3DRD1DRD4DRD5 | |
| Hydrochloric Acid SCHEMBL11514533 | 0.91 | DRD2 (0.82) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL23309922 | 0.87 | HIF1A (0.77) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL31366413 | 0.87 | HIF1A (0.77) | DRD2DRD3DRD1DRD4DRD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 148 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4378532-B1 | COMPOUNDS AND METHODS FOR TREATING FIBROTIC PATHOLOGIES | MAYO FOUND MEDICAL EDUCATION & RES (US) | 2025-11-12 | — | — | EP | claimed |
| US-20250179086-A1 | COMPOUNDS AND METHODS FOR TREATING FIBROTIC PATHOLOGIES | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2025-06-05 | — | — | US | claimed |
| US-20240252463-A1 | METHODS OF TREATING FIBROTIC PATHOLOGIES | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2024-08-01 | — | — | US | claimed |
| EP-3745862-B1 | D1 DOPAMINE RECEPTOR AGONISTS FOR TREATING FIBROTIC PATHOLOGIES | MAYO FOUND MEDICAL EDUCATION & RES (US) | 2024-06-26 | — | — | EP | claimed |
| EP-4378532-A2 | COMPOUNDS AND METHODS FOR TREATING FIBROTIC PATHOLOGIES | Mayo Foundation for Medical Education and Research (US) | 2024-06-05 | — | — | EP | claimed |
| US-20230346740-A1 | METHODS OF TREATING FIBROTIC PATHOLOGIES | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2023-11-02 | — | — | US | claimed |
| EP-4003348-A1 | COMPOUNDS AND METHODS FOR TREATING FIBROTIC PATHOLOGIES | Mayo Foundation for Medical Education and Research (US) | 2022-06-01 | — | — | EP | claimed |
| US-20210038561-A1 | METHODS OF TREATING FIBROTIC PATHOLOGIES | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2021-02-11 | — | — | US | claimed |
| WO-2021021922-A1 | COMPOUNDS AND METHODS FOR TREATING FIBROTIC PATHOLOGIES | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2021-02-04 | — | — | WO | claimed |
| EP-3745862-A1 | METHODS OF TREATING FIBROTIC PATHOLOGIES | Mayo Foundation for Medical Education and Research (US) | 2020-12-09 | — | — | EP | claimed |
| US-20170112829-A1 | USE OF COMPOUNDS BINDING TO THE SIGMA RECEPTOR LIGANDS FOR THE TREATMENT OF NEUROPATHIC PAIN DEVELOPING AS A CONSEQUENCE OF CHEMOTHERAPY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2017-04-27 | — | — | US | claimed |
| US-20110052723-A1 | USE OF COMPOUNDS BINDING TO THE SIGMA RECEPTOR LIGANDS FOR THE TREATMENT OF NEUROPATHIC PAIN DEVELOPING AS A CONSEQUENCE OF CHEMOTHERAPY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-03-03 | — | — | US | claimed |
| WO-2010101649-A2 | SIGMA 1 RECEPTOR INHIBITION AS A NOVEL THERAPEUTICAL APPROACH AGAINST HEPATITIS C VIRUS INFECTION | GASTAMINZA PABLO (US) | 2010-09-10 | — | — | WO | claimed |
| US-20090325975-A1 | Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-12-31 | — | — | US | claimed |
| EP-2090311-A1 | Use of compounds binding to the sigma receptor ligands for the treatment of neuropathic pain developing as a consequence of chemotherapy | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2009-08-19 | — | — | EP | claimed |
| US-20090042898-A1 | USE OF COMPOUNDS ACTIVE ON THE SIGMA RECEPTOR FOR THE TREATMENT OF MECANICAL ALLODYNIA | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2009-02-12 | — | — | US | claimed |
| EP-1829534-A1 | Use of compounds binding to the sigma receptor for the treatment of metabolic syndrome | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-09-05 | — | — | EP | claimed |
| CN-1988896-A | Use of compounds active on the sigma receptor for the treatment of mechanical allodynia | ESTEVE LABOR DR (ES) | 2007-06-27 | — | — | CN | claimed |
| EP-1787679-A1 | Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-05-23 | — | — | EP | claimed |
| EP-0167204-B1 | METHOD FOR IMPROVING THE ABSORPTION AND EFFECTIVENESS OF A CATECHOLAMINE COMPOUND | SIMES S.p.A. Società Italiana Medicinali e Sintetici (IT) | 1989-09-27 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179086-A1 | COMPOUNDS AND METHODS FOR TREATING FIBROTIC PATHOLOGIES | MMP1, MMP8, COL2A1 | DRD2 4882/4885DRD3 4873/4885DRD1 4883/4885 |
| US-20090042898-A1 | USE OF COMPOUNDS ACTIVE ON THE SIGMA RECEPTOR FOR THE TREATMENT OF MECANICAL ALLODYNIA | OPRM1, OPRL1, OPRK1 | DRD2 240/4885DRD3 345/4885DRD1 519/4885 |
| US-20210038561-A1 | METHODS OF TREATING FIBROTIC PATHOLOGIES | MMP1, MMP8, COL2A1 | DRD2 4879/4885DRD3 4860/4885DRD1 4882/4885 |
| US-20240252463-A1 | METHODS OF TREATING FIBROTIC PATHOLOGIES | MMP1, MMP8, COL2A1 | DRD2 4879/4885DRD3 4860/4885DRD1 4882/4885 |
| US-20230346740-A1 | METHODS OF TREATING FIBROTIC PATHOLOGIES | MMP1, MMP8, COL2A1 | DRD2 4879/4885DRD3 4860/4885DRD1 4882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.